2016 (19 POSTS)
Cui Y, Li J, Weng L, Wirbisky SE , Freeman JL, Liu J, Liu Q, Yuan X, Irudayaraj J. 2016. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget 7(49):81698–81714; doi: 10.18632/oncotarget.13173 .
View Abstract
Publication: Manuscripts
Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA , et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.
View Abstract
Publication: Manuscripts
Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA . 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181. doi: 10.1007/s12029-016-9809-5 .
View Abstract
Publication: Abstracts and Presentations
Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA , Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4:1 http://dx.doi.org/10.4172/2329-6917.1000208
View Abstract
Publication: Manuscripts
Erichsen R, Kelsh MA , Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7): 500–503.
View Abstract
Publication: Manuscripts
Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M , et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica . 101(12):1524–1533. doi: 10.3324/haematol.2016.144311.
View Abstract
Publication: Manuscripts
Gökbuget N, Kelsh M , Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.
View Abstract
Publication: Manuscripts
Panko JM , Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.
View Abstract
Publication: Abstracts and Presentations
Lancet JE, Sacks NC, Cyr PL , Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.
Publication: Abstracts and Presentations
Sacks NC , Noone J, Cyr PL , Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.
Publication: Abstracts and Presentations
Sacks NC , Cyr P , Liu Y , Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780 .
View Abstract
Publication: Abstracts and Presentations
Sacks NC , Noone J, Cyr PL , Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051 .
View Abstract
Publication: Abstracts and Presentations
Sacks NC , Sharma A, Cyr PL , Liu Y , Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523 .
View Abstract
Publication: Abstracts and Presentations , Manuscripts
Pierce JS, Ruestow PS, Finley BL . An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Poster presentation at American Industrial Hygiene Conference & Exposition (AIHce), 2016.
Publication: Abstracts and Presentations
Suh M , Thompson CM , Brorby GP , Mittal L , Proctor DM . 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009 .
View Abstract
Publication: Manuscripts
Pierce JS, Ruestow PS, Finley BL . An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Abstract #2139. Poster presentation at Society of Toxicology 55th Annual Meeting, New Orleans, LA, 2016.
Publication: Abstracts and Presentations
Benson SM, Batdorf S, Hitchcock KM, Galbraith DA, Finley BL . Asbestos exposure and pharyngeal and laryngeal cancer risk: A fiber-type specific meta-analysis. Abstract #2974. Poster presentation at Society of Toxicology 55th Annual Meeting, New Orleans, LA, 2016.
Publication: Abstracts and Presentations
Proctor DM . Cancer risk assessment for ingested hexavalent chromium: Challenges and controversies – Introduction. [session introduction; no abstract]. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.
Publication: Abstracts and Presentations
Brorby GP , Suh M , Thompson CM , Mittal L , Proctor DM . Inhalation cancer risk assessment of cobalt metal. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.
View Abstract
Publication: Abstracts and Presentations
2015 (5 POSTS)
Proctor DM , Suh M , Mittal L , Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol 26(2):224-231. doi: 10.1038/jes.2015.77 .
View Abstract